Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Metrics to compare | EVGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVGNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.6x | −2.1x | −0.4x | |
PEG Ratio | −0.01 | 0.28 | 0.00 | |
Price/Book | −100.8x | 1.5x | 2.6x | |
Price / LTM Sales | 2.1x | 2.9x | 3.2x | |
Upside (Analyst Target) | - | 686.5% | 50.6% | |
Fair Value Upside | Unlock | 12.9% | 6.6% | Unlock |